- Home
- LGVN vs COEP Comparison
LGVN vs COEP Comparison
Compare LGVN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- COEP
- Stock Information
- Founded
- LGVN 2014
- COEP 2017
- Country
- LGVN United States
- COEP United States
- Employees
- LGVN N/A
- COEP 7
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGVN Health Care
- COEP Health Care
- Exchange
- LGVN Nasdaq
- COEP Nasdaq
- Market Cap
- LGVN 26.0M
- COEP 22.3M
- IPO Year
- LGVN 2021
- COEP N/A
- Fundamental
- Price
- LGVN $1.70
- COEP $9.27
- Analyst Decision
- LGVN Strong Buy
- COEP
- Analyst Count
- LGVN 3
- COEP 0
- Target Price
- LGVN $8.67
- COEP N/A
- AVG Volume (30 Days)
- LGVN 314.6K
- COEP 1.0M
- Earning Date
- LGVN 02-25-2025
- COEP 11-13-2024
- Dividend Yield
- LGVN N/A
- COEP N/A
- EPS Growth
- LGVN N/A
- COEP N/A
- EPS
- LGVN N/A
- COEP N/A
- Revenue
- LGVN $1,852,000.00
- COEP N/A
- Revenue This Year
- LGVN $208.32
- COEP N/A
- Revenue Next Year
- LGVN $43.96
- COEP N/A
- P/E Ratio
- LGVN N/A
- COEP N/A
- Revenue Growth
- LGVN 141.46
- COEP N/A
- 52 Week Low
- LGVN $0.77
- COEP $2.31
- 52 Week High
- LGVN $10.30
- COEP $13.58
- Technical
- Relative Strength Index (RSI)
- LGVN 41.48
- COEP 75.88
- Support Level
- LGVN $1.72
- COEP $6.22
- Resistance Level
- LGVN $1.89
- COEP $10.00
- Average True Range (ATR)
- LGVN 0.14
- COEP 1.79
- MACD
- LGVN -0.00
- COEP 0.43
- Stochastic Oscillator
- LGVN 8.47
- COEP 90.51
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.